EFFECTIVENESS OF TELENUTRITION EDUCATION, GROUP LIFESTYLE BALANCE PROGRAM, FOR WEIGHT LOSS AND IMPROVEMENT IN DIETARY PATTERN AMONG MYANMAR ADULTS WITH OVERWEIGHT AND OBESITY

Phase 1

Completed

• Conditions: Overweight and obesity in Myanmar adults with no underlying comorbid diesases; Obesity; Lifestyle therapy; Behavioural therapy

• Registration Number: TCTR20230508001
• Lead Sponsor: yan Hlaing Bwar

Brief Summary

This study demonstrated that application of telenutrition platform to deliver the GLB program is effective in helping Myanmar adults with overweight and obesity to achieve significant weight loss within a relatively short time frame (i.e., 12 weeks). A significant overall decrease in weight and increase in reported physical activity were noted, which have been proven to improve diabetes, non-alcoholic fatty liver disease (NAFLD), dyslipidemia, and hypertension.

Detailed Description

Not available

Study Timeline

• Study Completion: 2022-09-18
• Study Start: 2023-05-08
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 23

Inclusion Criteria

1. Myanmar adults aged 20-55 years
2. BMI 25 kg/m2 and above
3. Must have an either smartphone/laptop/iPad/tablet with a video conferencing platform and Internet Connection.
4. Must be able to use Internet, E-mail, video conferencing platform

Exclusion Criteria

1. Any underlying medical illness which will encompass diabetes , cardiovascular diseases, hypertension, any types of cancer, any active renal and hepatic diseases, any active pulmonary diseases, any serious gastrointestinal diseases such as pancreatitis, inflammatory bowel disease, and any endocrine disorders e.g., Thyroid disease, phaeochromocytoma, Cushing's syndrome, etc.
2. Recent abdominal, thoracic, neuro, and orthopaedic surgery which may affect the intervention.
3. Being pregnant or lactating
4. Major psychotic disorders which may interfere with intervention including but not limited to depression, anxiety disorder, schizophrenia, bipolar disorder, etc.
5. People currently taking medications for weight loss e.g. orlistat, liraglutide, semaglutide, bupropion/naltrexone, people following certain diet plans or serious food allergies which may interfere with the intervention, e.g. ketogenic diet, renal diet, and people with more than 10% of weight loss in past 6 months

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Body weight weekly up to 11th week Weighing scale,Vegetables and fruits intake weekly up to 11th week 3-days food record,Saturated fat intake 12th week at the end of intervention 3-day food record and INMUCAL software 4.0,Energy intake weekly up to 11th week 3-day food record and INMUCAL software 4.0,People who achieve weight loss 7% at the end of intervention (%) 12 th week at the end of intervention Weighing scale,People who achieve 5% weight loss at the end of intervention (%) 12th at the end of intervention Weighing scale ,People who achieve total fat intake less than 25% and saturated fat intake less than 10% at the end of intervention (%) 12th week at the end of intervention 3-day food record and INMUCAL software 4.0,People who achieve physical goals at the end of intervention (%) 12th week at the end of intervention daily physical activity monitor booklet

Secondary Outcome Measures

Name	Time	Method
Food Group Diversity Score 12th week at the end of intervention Diet Quality Questionnaire (DQQ),Participants who attend at least half of the classes (%) 12th week at the end of intervention attendance record